



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute Form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

8

Complete if Known

Application Number	10/821,256
Filing Date	April 8, 2004
First Named Inventor	Benner et al.
Group Art Unit	1644
Examiner Name	Y. Kim
Attorney Docket Number	2183.03-6420US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US - 2002/0147306 A1	10-2002	Lin et al.	
		US - 2003/0148955	08-2003	Pluenneke	
		US - 2004/0208885 A1	10-21-2004	Khan et al.	
		US - 2005/0037430 A1	02-17-2005	Khan et al.	
		US - 2005/0107314 A1	05-2005	Gorczynski et al.	
		US - 2005/0214943 A1	09-29-2005	Khan et al.	
		US - 2005/0227925 A1	10-13-2005	Benner et al.	
		US - 2006/0111292 A1	05-25-2006	Khan et al.	
		US - 2006/0142205 A1	06-29-2006	Benner et al.	
		US - 4,330,466	05-1982	Yanaihara et al.	
		US - 4,427,660	01-1984	Schiffman et al.	
		US - 4,571,336	02-1986	Houck et al.	
		US - 4,753,965	06-1988	Stemerick et al.	
		US - 4,855,285	08-1989	Stevens	
		US - 5,002,961	03-1991	Dage et al.	
		US - 5,055,447	10-1991	Palladino et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		WO 98/34631 A1	08-1998	Thomas Jefferson University		
		WO 2001/83554 A2	11-2001	Praecis Pharmaceuticals Incorporated et al.		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 8

Complete if Known

Application Number	10/821,256
Filing Date	April 8, 2004
First Named Inventor	Benner et al.
Group Art Unit	1644
Examiner Name	Y. Kim
Attorney Docket Number	2183.03-6420US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US - 5,223,397	06-1993	Pouletty	
		US - 5,801,193	09-1998	Ojo-Amaize et al.	
		US - 5,854,004	12-1998	Czemilofsky et al.	
		US - 5,856,440	01-1999	Wang	
		US - 5,942,494	08-1999	Ginsberg et al.	
		US - 5,972,924	10-1999	Keep et al.	
		US - 5,966,712	10-12-1999	Sabatini et al.	
		US - 5,981,486	11-1999	Matsushima et al.	
		US - 5,994,126	11-1999	Steinman et al.	
		US - 6,051,596	04-2000	Badger	
		US - 6,075,150	06-2000	Wang et al.	
		US - 6,150,500	11-2000	Salerno	
		US - 6,235,281	05-2001	Stenzel et al.	
		US - 6,278,794	08-21-2001	Parekh et al.	
		US - 6,310,041	10-2001	Haddox et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.**

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

8

Complete if Known

Application Number	10/821,256
Filing Date	April 8, 2004
First Named Inventor	Benner et al.
Group Art Unit	1644
Examiner Name	Y. Kim
Attorney Docket Number	2183.03-6420US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ABEYAMA et al., A role of NF-κB-dependent gene transactivation in sunburn. The Journal of Clinical Investigation, Vol. 105, No. 12, pp. 1751-59, June 2000.	
		ABRAHAM, E., "Coagulation Abnormalities in Acute Lung Injury and Sepsis," Am. J. Respir. Cell Mol. Biol., 2000, pp. 401-404, Vol. 22.	
		ADIB-CONQUY et al., "NF-κB Expression in Mononuclear Cells in Patients with Sepsis Resembles That Observed in Lipopolysaccharide Tolerance," Am. J. Respir. Crit. Care Med., 2000, pp. 1877-1883, Vol. 162.	
		ARIMA et al., "IL-2-Induced Growth of CD8+ T Cell Prolymphocytic Leukemia Cells Mediated by NF-kappaB Induction and IL-2 Receptor alpha Expression," Leukemia Research, 1998, pp. 265-273, Vol. 22, No. 3.	
		BAEUERLE et al., "Function and Activation of NF-κB in the Immune System," Annu. Rev. Immunol., 1994, pp. 141-179, Vol. 12.	
		BETHEA et al., "Traumatic Spinal Cord Injury Induces Nuclear Factor-κB Activation," The Journal of Neuroscience, 1 May 1998, pp. 3251-3260, Vol. 18, No. 9.	
		BODFISH et al., "Treating the Core Features of Autism: Are We There Yet?" Mental Retardation and Developmental Disabilities Research Reviews, 2004, pp. 318-326, Vol. 10.	
		BRADHAM et al., Activation of nuclear factor- κB during orthotopic liver transplantation in rats is protective and does not require Kupffer cells, Liver Transplantation and Surgery, July 1999, pp. 282-93, Vol. 5, No. 4.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

5

of

8

Complete if Known

Application Number	10/821,256
Filing Date	April 8, 2004
First Named Inventor	Benner et al.
Group Art Unit	1644
Examiner Name	Y. Kim
Attorney Docket Number	2183.03-6420US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BROWN et al., "Two Forms of NF-kappaB1 (p105/p50) in Murine Macrophages: Differential Regulation by Lipopolysaccharide, Interleukin-2, and Interferon-gamma," Journal of Interferon and Cytokine Research, 1997, pp. 295-306, Vol. 17.	
		COOK et al., Modified total lymphoid irradiation and low dose corticosteroids in progressive multiple sclerosis, Journal of Neurological Sciences, Vol. 152, pp. 172-81, 1997.	
		CUI et al., Am. J. Physiol. Integr. Comp. Physiol., 2004, pp. R699-R709, Vol. 286.	
		DE SAIZIEU et al., Journal of Bacteriology, Vol. 182, No. 17, pp. 4696-4703, September 2000.	
		DECHEND et al., Oncogene, Vol. 18, pp. 3316-3323, 1999.	
		EMMEL et al., "Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T Cell Activation," Science, 22 December 1989, pp. 1617-1620, Vol. 246.	
		EPINAT et al., "Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway," Oncogene, 1999, pp. 6896-6909, Vol. 18.	
		FASSIO et al., Transforming Growth Factor Alpha and Its Receptor in Neural Retina, Investigative Ophthalmology & Visual Science, September 1989, pp. 1916-1922, Vol. 30, No. 9.	
		FAUST et al., "Disseminated intravascular coagulation and purpura fulminans secondary to infection," Bailliere's Clinical Haematology, 2000, 179-197, Vol. 13, No. 2.	
		FLORES et al., NFkappaB and AP-1 DNA binding activity in patients with multiple sclerosis. J. Neuroimmunol. Vol. 135, No. 1-2, pp. 141-7, February 2003.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

6

of

8

Complete if Known

Application Number	10/821,256
Filing Date	April 8, 2004
First Named Inventor	Benner et al.
Group Art Unit	1644
Examiner Name	Y. Kim
Attorney Docket Number	2183.03-6420US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		GenBank Accession No. NP_000728, GI: 4502789, publicly available April 2007.	
		HAN et al., Cholecystokinin induction of mob-1 chemokine expression in pancreatic acinar cells requires NF-kappaB activation, American Journal of Physiology, July 1999, Vol. 277, pp. C74-C82.	
		ICHIYAMA et al., Systemically administered alpha-melanocyte-stimulating peptides inhibit NF-kappaB activation in experimental brain inflammation, Brain Research, July 1999, pp. 31-37, Vol. 836.	
		JIMENEZ-GARZA et al., "Early Effects of Modulating Nuclear factor-kappaB Activation on Traumatic Spinal Cord Injury in Rats," Ann. N.Y. Acad. Sci., 2005, pp. 148-150, Vol. 1053.	
		KALNS et al., Biochem. Biophys. Res. Comm., 2002, pp. 41-44, Vol. 292.	
		KALNS et al., Biochem. Biophys. Res. Comm., 2002, pp. 506-09, Vol. 297.	
		Keeton and Gould, Biological Science, 5th Ed., New York, W.W. Norton & Company, Inc. 1993, p. 4.	
		KIDD et al., "Autism, An Extreme Challenge to Integrative Medicine. Part II: Medical Management," Alternative Medicine Review, 2002, pp. 472-499, Vol. 7, No. 6.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

7

of

8

Complete if Known

Application Number	10/821,256
Filing Date	April 8, 2004
First Named Inventor	Benner et al.
Group Art Unit	1644
Examiner Name	Y. Kim
Attorney Docket Number	2183.03-6420US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KRONFOL et al., "Cytokines and the Brain: Implications for Clinical Psychiatry," Am. J. Psychiatry, May 2000, pp. 683-694, Vol. 157, No. 5.	
		LI et al., "NF-kappaB Regulation in the Immune System," Nature Reviews/Immunology, October 2002, pp. 725-734, Vol. 2.	
		LIN et al., The Journal of Biological Chemistry, Vol. 270, No. 24, pp. 14255-58, June 1995.	
		MALEK-AHMADI, P., "Role of Cytokines in Psychopathology: Therapeutic Implications," Drug News Prospects, June 1998, pp. 271-276, Vol. 11, No. 5.	
		MALYAK et al., Characterization of a Low Molecular Weight Isoform of IL-1 Receptor Antagonist, The Journal of Immunology, 1998, pp. 1997-2003, Vol. 161.	
		MCBEAN et al., "Rodent Models of Global Cerebral Ischemia: A Comparison of Two-Vessel Occlusion and Four-Vessel Occlusion," Gen. Pharmac., 1998, pp. 431-434, Vol. 30, No. 4.	
		MCDONALD et al., "Interleukin-15 (IL-15) Induces NF-kappaB Activation and IL-8 Production in Human Neutrophils," Blood, 15 December 1998, pp. 4828-4835, Vol. 92, No. 12.	
		MOAYERI et al., Journal of Clinical Investigation, September 2003, pp. 670-82, Vol. 112, No. 5.	
		NEELY et al., "Then and now: Studies using a burned mouse model reflect trends in burn research over the past 25 years," Burns, 1999, pp. 603-609, Vol. 25.	
		OHLSSON et al., Interleukin-1 Receptor Antagonist Reduces Mortality from Endotoxin Shock, Nature, Dec. 6, 1990, pp. 550-552, Vol. 348.	
		OKA et al., Immunosuppression in organ transplantation, Japanese Journal of Pharmacology, Vol. 71, No. 2, pp. 89-100, June 1996.	
		OLSZYNA et al., Levels of Inhibitors of Tumor Necrosis Factor Alpha and Interleukin 1b in Urine and Sera of Patients with Urosepsis, Infection and Immunity, Aug. 1998, pp. 3527-34.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

8

of

8

Complete if Known

Application Number	10/821,256
Filing Date	April 8, 2004
First Named Inventor	Benner et al.
Group Art Unit	1644
Examiner Name	Y. Kim
Attorney Docket Number	2183.03-6420US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PCT International Search Report, International Application No. PCT/NL02/00639, mailed August 4, 2003.	
		PCT International Search Report, PCT/NL01/00259, dated December 18, 2001.	
		PELLIZZARI et al., FEBS Letters, 1999, pp. 199-204, Vol. 462.	
		SAMANIEGO et al., "Induction of Programmed Cell Death in Kaposi's Sarcoma Cells by Preparations of Human Chorionic Gonadotropin," Journal of the National Cancer Institute, January 20, 1999, pp. 135-43, Vol. 91, No. 2.	
		SMITH et al., "Recent developments in drug therapy for multiple sclerosis," Multiple Sclerosis, 1999, pp. 110-120, Vol. 5.	
		TRAYSTMAN, R., "Animal Models of Focal and Global Cerebral Ischemia," ILAR Journal, 2003, pp. 85-95, Vol. 44, No. 2.	
		WEINBERGER et al., "Mechanisms Mediating the Biologic Activity of Synthetic Proline, Glycine, and Hydroxyproline Polypeptides in Human Neutrophils," Mediators of Inflammation, 2005, pp. 31-38, Vol. 1.	
		YANG et al., "Increased cortical nuclear factor κ B (NF- κ B) DNA binding activity after traumatic brain injury in rats," Neuroscience Letters, 1995, pp. 101-104, Vol. 197.	
		ZHOU et al., Transplantation tolerance in NF- κ B-impaired mice is not due to regulation but is prevented by transgenic expression of Bcl-xL. The Journal of Immunology, Vol. 174, No. 6, pp. 3447-53, March 2005.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.